Cargando…

What Is the Role of Gut Microbiota in Obesity Prevalence? A Few Words about Gut Microbiota and Its Association with Obesity and Related Diseases

Obesity is becoming the most dangerous lifestyle disease of our time, and its effects are already being observed in both developed and developing countries. The aim of this study was to investigate the impact of gut microbiota on the prevalence of obesity and associated morbidities, taking into cons...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tokarek, Julita, Gadzinowska, Joanna, Młynarska, Ewelina, Franczyk, Beata, Rysz, Jacek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777962/ https://www.ncbi.nlm.nih.gov/pubmed/35056501 http://dx.doi.org/10.3390/microorganisms10010052

Ejemplares similares

The Role of the Microbiome-Brain-Gut Axis in the Pathogenesis of Depressive Disorder
por: Młynarska, Ewelina, et al.
Publicado: (2022)

Does the Composition of Gut Microbiota Affect Hypertension? Molecular Mechanisms Involved in Increasing Blood Pressure
por: Tokarek, Julita, et al.
Publicado: (2023)

The Impact of CKD on Uremic Toxins and Gut Microbiota
por: Rysz, Jacek, et al.
Publicado: (2021)

Molecular Processes Involved in the Shared Pathways between Cardiovascular Diseases and Diabetes
por: Tokarek, Julita, et al.
Publicado: (2023)

Gut microbiota in obesity
por: Liu, Bing-Nan, et al.
Publicado: (2021)

Molecular Interactions of Arterial Hypertension in Its Target Organs
por: Kućmierz, Joanna, et al.
Publicado: (2021)

Gut microbiota phenotypes of obesity
por: Stanislawski, Maggie A., et al.
Publicado: (2019)

Gut microbiota’s impact on obesity
por: Jeong, Sujin
Publicado: (2023)

Empagliflozin—A New Chance for Patients with Chronic Heart Failure
por: Kowalska, Klaudia, et al.
Publicado: (2021)

The Influence of SARS-CoV-2 Infection on Lipid Metabolism—The Potential Use of Lipid-Lowering Agents in COVID-19 Management
por: Kowalska, Klaudia, et al.
Publicado: (2022)

New Insights into Molecular Mechanisms of Chronic Kidney Disease
por: Frąk, Weronika, et al.
Publicado: (2022)

Acute Kidney Injury in COVID-19
por: Głowacka, Marta, et al.
Publicado: (2021)

Arterial Hypertension—Oxidative Stress and Inflammation
por: Krzemińska, Julia, et al.
Publicado: (2022)

Rhabdomyolysis-Induced AKI (RIAKI) Including the Role of COVID-19
por: Młynarska, Ewelina, et al.
Publicado: (2022)

The Influence of Lifestyle and Treatment on Oxidative Stress and Inflammation in Diabetes
por: Wronka, Magdalena, et al.
Publicado: (2022)

Chronic Kidney Disease as a Comorbidity in Heart Failure
por: Szlagor, Magdalena, et al.
Publicado: (2023)

Structural and Functional Changes in Aging Kidneys
por: Dybiec, Jill, et al.
Publicado: (2022)

New Insights into the Use of Liraglutide—Impact on Cardiovascular Risk and Microvascular Outcomes
por: Wronka, Magdalena, et al.
Publicado: (2023)

Association between the Gut Microbiota and Obesity
por: Mitev, Kiril, et al.
Publicado: (2019)

Characteristics of gut microbiota in people with obesity
por: Duan, Mengmeng, et al.
Publicado: (2021)

Impact of Exercise on Gut Microbiota in Obesity
por: Aragón-Vela, Jerónimo, et al.
Publicado: (2021)

Gut microbiota and obesity: New insights
por: Sarmiento-Andrade, Yoredy, et al.
Publicado: (2022)

The critical role of gut microbiota in obesity
por: Cheng, Zilu, et al.
Publicado: (2022)

Renal Cell Cancer and Obesity
por: Gluba-Brzózka, Anna, et al.
Publicado: (2022)

Cardiovascular Diseases: Therapeutic Potential of SGLT-2 Inhibitors
por: Frąk, Weronika, et al.
Publicado: (2023)

Pathophysiology of Cardiovascular Diseases: New Insights into Molecular Mechanisms of Atherosclerosis, Arterial Hypertension, and Coronary Artery Disease
por: Frąk, Weronika, et al.
Publicado: (2022)

Management of Familial Hypercholesterolemia with Special Emphasis on Evinacumab
por: Krzemińska, Julia, et al.
Publicado: (2022)

The Importance of SGLT-2 Inhibitors as Both the Prevention and the Treatment of Diabetic Cardiomyopathy
por: Kowalska, Klaudia, et al.
Publicado: (2022)

New Insights into the Use of Empagliflozin—A Comprehensive Review
por: Forycka, Joanna, et al.
Publicado: (2022)

Microbiota-gut-brain axis: relationships among the vagus nerve, gut microbiota, obesity, and diabetes
por: Longo, Susanna, et al.
Publicado: (2023)

Childhood Obesity: A Role for Gut Microbiota?
por: Sanchez, Marina, et al.
Publicado: (2014)

Gut Microbiota: A Contributing Factor to Obesity
por: Harakeh, Steve M., et al.
Publicado: (2016)

The role of Gut Microbiota in the development of obesity and Diabetes
por: Baothman, Othman A., et al.
Publicado: (2016)

Gut Microbiota and Obesity: A Role for Probiotics
por: Abenavoli, Ludovico, et al.
Publicado: (2019)

Effect of Diet on the Gut Microbiota Associated with Obesity
por: Kim, Bohkyung, et al.
Publicado: (2019)

Obesity, Early Life Gut Microbiota, and Antibiotics
por: Wilkins, Alyssa T., et al.
Publicado: (2021)

Association of gut microbiota with obesity in children and adolescents
por: Cho, Ky Young
Publicado: (2022)

What’s gut got to do with it? The role of the microbiota and inflammation in the development of adiposity and obesity
por: Jennings, Travis, et al.
Publicado: (2023)

Does the Gut Microbiota Contribute to Obesity? Going beyond the Gut Feeling
por: Aguirre, Marisol, et al.
Publicado: (2015)

The Gut-Brain Axis, the Human Gut Microbiota and Their Integration in the Development of Obesity
por: Bliss, Edward S., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_tipgs99fl89l0advdo6ovftkst